FDA official to receive ASH Outstanding Service Award
Click Here to Manage Email Alerts
The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.
The award recognizes an individual who has worked to raise public awareness and increase research funding for hematologic diseases.
Marks, director of FDA’s Center for Biologics Evaluation and Research, oversees the center’s work of ensuring the effectiveness and safety of biological products such as vaccines, blood and blood products, and cellular, tissue and gene therapies.
He will be honored for his commitment to hematology by overseeing approval of therapies that improve the quality of life for individuals with blood disorders.
“ASH is pleased to honor Dr. Marks, under whose leadership the FDA has made incredible advancements in the field of hematology, including overseeing the approvals of innovative cellular and gene-based therapies and working to streamline the regulatory process to get innovative therapies to patients in need,” ASH President Martin S. Tallman, MD, chief of the leukemia service at Memorial Sloan Kettering Cancer Center, said in an ASH-issued press release. “Dr. Marks has a long history of engagement as a member of ASH and as a valued friend to the society through his role at the FDA. His support and leadership have contributed to the success of joint ASH-FDA programs in recent years, as well as to the ongoing efforts to explore the use of clinically relevant real-world sickle cell disease and thalassemia data for research.”
Read more about
Click Here to Manage Email Alerts